Adolore’s Kv7-activating rdHSV-CA8 Therapy, now qualified for Erythromelalgia treatment

Introduction

Adolore BioTherapeutics, a leading biotech face known for its consistent efforts for establishing gene-therapy related treatments for chronic pain with the help of creative and safe CA8 analgesic peptides and rdHSV vector for main delivery. The company is proving its role and responsibility for conditions such as osteoarthritis, knee pain, and erythromelalgia. Since 2021, the company has been modernising the preclinical programs.

The heavy funding of $2.5 million in convertible debt and a valuable partnership with the University of Pittsburgh for its promising vector technology build the biggest strength for the company’s existing and future endeavours.

Announcement

Adolore have finally received approval for Orphan Drug Designation (ODD) for its impeccable Kv7-activating rdHSV-CA8 gene therapy. The therapy can now be considered for erythromelalgia (EM) at the initial and secondary stages.

How will the therapy work at the primary and secondary stages?

The EM’s primary stage involves the functional mutations in the SCN9A gene, which allows the Nav1.7 sodium channel, which is found in a few autonomic nerves and sensory neurons that ease the sodium channels to charge up. This aggressive condition promotes hyperexcitability in pain-detecting neurons.

Adolore’s activation of Kv7 channels through CA8 gene therapy can fight back against this hyperexcitability by sensing and targeting the actual ground reason of EM. The certification of Adolore’s idea is followed by the genetic studies of EM's familiar areas. Those areas give hope to the extreme chronic pain emerged because of the neuronal Nav1.7 sodium channel mutations.

Need

This ODD sheds safe light on EM patients’ hope, as the alternative to non-opioid analgesic treatment for chronic pain is registered in the market. By elevating the rdHSV-CA8 gene therapy, the company is effectively modernising the two preclinical development programs.

Two preclinical development programs

Adolore’s main development program for chronic pain due to knee osteoarthritis is backed by UG3/UH3 funds, with permission from the NIH/NINDS/HEAL Program for all uniformed GCP/GMP/GLP development initiatives via first-in-human study. The other preclinical space can meet the contribution of the rdHSV-CA8 gene therapy for the rare, genetically driven, extreme neuropathic pain caused by EM.

In both applications, the Kv7 activating rdHSV-CA8 gene therapy can play a crucial role and accelerate the growth of the preclinical development programs. This has opened a new pathway for treating patients who were left unsatisfied or were not even introduced to the clinical studies.